Article info
PDFClinical science
Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY)
- Correspondence to Vishali Gupta, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research,Chandigarh, India;vishalisara{at}yahoo.co.in; vishalisara{at}gmail.com
Citation
Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY)
Publication history
- Received July 5, 2020
- Revised August 29, 2020
- Accepted September 23, 2020
- First published October 3, 2020.
Online issue publication
May 11, 2023
Article Versions
- Previous version (11 May 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the COVID-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage